Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Dolutegravir/Rilpivirine (Juluca -- ViiV healthcare) indication : the treatment of human immunodeficiency virus (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL)

The CADTH Canadian Drug Expert Committee (CDEC) recommends that dolutegravir/rilpivirine (DTG/RPV) be reimbursed as a complete regimen to replace the current antiretroviral (cARV) regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically stabl...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2018, June 2018
Edition:Version 1.0. (Final)
Series:CADTH common drug review
Subjects:
Insurance, Health, Reimbursement
Canada
Hiv Integrase Inhibitors / Therapeutic Use
Reverse Transcriptase Inhibitors / Therapeutic Use
Cost-benefit Analysis
Reverse Transcriptase Inhibitors / Economics
Hiv Infections / Drug Therapy
Hiv Integrase Inhibitors / Economics
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that dolutegravir/rilpivirine (DTG/RPV) be reimbursed as a complete regimen to replace the current antiretroviral (cARV) regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically stable and suppressed (i.e., fewer than 50 copies per mL of HIV-1 ribonucleic acid [RNA]), if the following criterion and condition are met: Under the care of a practitioner experienced in the care of patients with HIV; A reduced price
Physical Description:1 PDF file (6 pages)

Similar Items